Radiopharmaceutical company Radionetics Oncology has secured $82.5 million in a Series A funding round led by Frazier Life Sciences, 5AM Ventures, and existing investors DCVC Bio, Crinetics Pharmaceuticals and GordonMD Global Investments. San Diego-based Radionetics was advised by a Wilson Sonsini Goodrich & Rosati team including partner Mike Hostetler.
Biotech & Pharmaceuticals
January 04, 2024, 11:07 AM